ArticleOpen forum infectious diseases2019

The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections.

Mark Redell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.